Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Brain Histamine N-Methyltransferase As a Possible Target of Treatment for Methamphetamine Overdose.

Kitanaka J, Kitanaka N, Hall FS, Uhl GR, Takemura M.

Drug Target Insights. 2016 Mar 2;10:1-7. doi: 10.4137/DTI.S38342. eCollection 2016. Review.

2.

The Effect of Subchronic Dosing of Ciproxifan and Clobenpropit on Dopamine and Histamine Levels in Rats.

Mahmood D, Pillai KK, Khanam R, Jahan K, Goswami D, Akhtar M.

J Exp Neurosci. 2015 Aug 31;9:73-80. doi: 10.4137/JEN.S27244. eCollection 2015.

3.

Effects of an H3R antagonist on the animal model of autism induced by prenatal exposure to valproic acid.

Baronio D, Castro K, Gonchoroski T, de Melo GM, Nunes GD, Bambini-Junior V, Gottfried C, Riesgo R.

PLoS One. 2015 Jan 5;10(1):e0116363. doi: 10.1371/journal.pone.0116363. eCollection 2015.

4.

Animal models of tic disorders: a translational perspective.

Godar SC, Mosher LJ, Di Giovanni G, Bortolato M.

J Neurosci Methods. 2014 Dec 30;238:54-69. doi: 10.1016/j.jneumeth.2014.09.008. Epub 2014 Sep 20. Review.

5.

Histamine H₃ receptors, the complex interaction with dopamine and its implications for addiction.

Ellenbroek BA.

Br J Pharmacol. 2013 Sep;170(1):46-57. doi: 10.1111/bph.12221. Review.

6.

Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil.

Uguen M, Perrin D, Belliard S, Ligneau X, Beardsley PM, Lecomte JM, Schwartz JC.

Br J Pharmacol. 2013 Jun;169(3):632-44. doi: 10.1111/bph.12149.

7.
8.

Histamine H3 receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectives.

Bhowmik M, Khanam R, Vohora D.

Br J Pharmacol. 2012 Dec;167(7):1398-414. doi: 10.1111/j.1476-5381.2012.02093.x. Review.

9.

Histamine h3 receptor: a novel therapeutic target in alcohol dependence?

Nuutinen S, Vanhanen J, Mäki T, Panula P.

Front Syst Neurosci. 2012 May 18;6:36. doi: 10.3389/fnsys.2012.00036. eCollection 2012.

10.

Histaminergic mechanisms for modulation of memory systems.

Köhler CA, da Silva WC, Benetti F, Bonini JS.

Neural Plast. 2011;2011:328602. doi: 10.1155/2011/328602. Epub 2011 Aug 18. Review.

11.

In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.

Darvesh AS, Carroll RT, Geldenhuys WJ, Gudelsky GA, Klein J, Meshul CK, Van der Schyf CJ.

Expert Opin Drug Discov. 2011 Feb;6(2):109-127.

12.

Alzheimer's disease and age-related memory decline (preclinical).

Terry AV Jr, Callahan PM, Hall B, Webster SJ.

Pharmacol Biochem Behav. 2011 Aug;99(2):190-210. doi: 10.1016/j.pbb.2011.02.002. Epub 2011 Feb 24. Review.

13.

Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease.

Bardgett ME, Davis NN, Schultheis PJ, Griffith MS.

Neurobiol Learn Mem. 2011 Jan;95(1):64-72. doi: 10.1016/j.nlm.2010.10.008. Epub 2010 Nov 10.

14.

The genetics of child psychiatric disorders: focus on autism and Tourette syndrome.

State MW.

Neuron. 2010 Oct 21;68(2):254-69. doi: 10.1016/j.neuron.2010.10.004. Review.

15.

Effects of a novel cognition-enhancing agent on fetal ethanol-induced learning deficits.

Savage DD, Rosenberg MJ, Wolff CR, Akers KG, El-Emawy A, Staples MC, Varaschin RK, Wright CA, Seidel JL, Caldwell KK, Hamilton DA.

Alcohol Clin Exp Res. 2010 Oct;34(10):1793-802. doi: 10.1111/j.1530-0277.2010.01266.x. Epub 2010 Jul 9.

16.

The H3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (dizocilpine) in rats.

Bardgett ME, Points M, Kleier J, Blankenship M, Griffith MS.

Neuropharmacology. 2010 Nov;59(6):492-502. doi: 10.1016/j.neuropharm.2010.07.004. Epub 2010 Jul 16.

17.

L-histidine decarboxylase and Tourette's syndrome.

Ercan-Sencicek AG, Stillman AA, Ghosh AK, Bilguvar K, O'Roak BJ, Mason CE, Abbott T, Gupta A, King RA, Pauls DL, Tischfield JA, Heiman GA, Singer HS, Gilbert DL, Hoekstra PJ, Morgan TM, Loring E, Yasuno K, Fernandez T, Sanders S, Louvi A, Cho JH, Mane S, Colangelo CM, Biederer T, Lifton RP, Gunel M, State MW.

N Engl J Med. 2010 May 20;362(20):1901-8. doi: 10.1056/NEJMoa0907006. Epub 2010 May 5.

18.

Effects of the cognition-enhancing agent ABT-239 on fetal ethanol-induced deficits in dentate gyrus synaptic plasticity.

Varaschin RK, Akers KG, Rosenberg MJ, Hamilton DA, Savage DD.

J Pharmacol Exp Ther. 2010 Jul;334(1):191-8. doi: 10.1124/jpet.109.165027. Epub 2010 Mar 22.

19.

Effects of the H(3) antagonist, thioperamide, on behavioral alterations induced by systemic MK-801 administration in rats.

Bardgett ME, Points M, Roflow J, Blankenship M, Griffith MS.

Psychopharmacology (Berl). 2009 Sep;205(4):589-97. doi: 10.1007/s00213-009-1566-8. Epub 2009 May 23.

20.

Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists.

Miller TR, Milicic I, Bauch J, Du J, Surber B, Browman KE, Marsh K, Cowart M, Brioni JD, Esbenshade TA.

Br J Pharmacol. 2009 May;157(1):139-49. doi: 10.1111/j.1476-5381.2009.00239.x.

Items per page

Supplemental Content

Write to the Help Desk